Open AccessIn Vitro Efficacy of High-Dose Tobramycin against Burkholderia cepacia Complex and Stenotrophomonas maltophilia Isolates from Cystic Fibrosis Patients
Author(s) -
Anina Ratjen,
Yvonne Yau,
Jillian Wettlaufer,
Larissa Matukas,
James E. A. Zlosnik,
David P. Speert,
John J. LiPuma,
Elizabeth Tullis,
Valerie Waters
Publication year - 2014
Publication title -
antimicrobial agents and chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.07
H-Index - 259
eISSN - 1070-6283
pISSN - 0066-4804
DOI - 10.1128/aac.04123-14
Subject(s) - stenotrophomonas maltophilia , burkholderia cepacia complex , tobramycin , burkholderia , cystic fibrosis , microbiology and biotechnology , stenotrophomonas , pseudomonas aeruginosa , biology , pseudomonas , antibiotics , bacteria , medicine , gentamicin , genetics
Burkholderia cepacia complex and Stenotrophomonas maltophilia infections are associated with poor clinical outcomes in persons with cystic fibrosis (CF). The MIC50 based on planktonic growth and the biofilm concentration at which 50% of the isolates tested are inhibited (BIC50) of tobramycin were measured for 180 B. cepacia complex and 101 S. maltophilia CF isolates and were 100 μg/ml for both species. New inhalation devices that deliver high tobramycin levels to the lung may be able to exceed these MICs.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom